TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07024693: DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy

Sponsor: Design Therapeutics, Inc. · Phase: PHASE2 · Area: RARE_ORPHAN · Target Enrollment: 70 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$16,480,000

Rescue Site Savings

+$10,866,500

Unlock Full NCT07024693 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07024693 Rescue Dossier →